Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shire Course Corrects Lifitegrast And Eyes Ophthalmology Prospects

This article was originally published in The Pink Sheet Daily

Executive Summary

The specialty pharma has worked with regulators to determine a next step for its late-stage eye drug and intends to build a business unit around the compound.

You may also be interested in...



Shire Sheds Dermagraft; Exits Regenerative Medicine

The Irish specialty pharma has divested an underperforming unit, but not without a significant write-off. Yet, investors and analysts applaud the decision.

New Shire CEO Has Big Ophthalmology Plans; SARcode Sets The Stage

With its third acquisition this year, Shire gains Phase III Lifitegrast in development for dry eye disease. It expects to launch the product in the U.S. in 2016.

Start-Ups, With An Eye On Success In Wet AMD, Tackle The Dry Form

“Early and primitive” is a term frequently used to describe drug development for dry AMD in discussions with experts. Several companies have brought products to Phase II trials, but none has met the efficacy endpoints. A new crop of start-ups is trying, driven by the huge unmet demand and emerging science.

Topics

Related Companies

UsernamePublicRestriction

Register

PS077235

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel